KIORA PHARMACEUTICALS INC
About KIORA PHARMACEUTICALS INC
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- -$10.8M
- Total assets
- $24.3M
- Market cap
- $11.1M
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $12.8M
- Operating income
- -$12.8M
- Income tax
- -$1.3M
- Net income
- -$10.8M
- EPS (basic)
- $-2.60
- EPS (diluted)
- $-2.64
Balance sheet
- Total assets
- $24.3M
- Current assets
- $21.7M
- Total liabilities
- $8.1M
- Current liabilities
- $3.6M
- Shareholders’ equity
- $16.1M
Cash flow
- Operating cash flow
- -$10.0M
- Investing cash flow
- $14.4M
- Financing cash flow
- $265.7K
- Net cash flow
- $4.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $11.1M
- EPS (diluted)
- $-2.64
- Shares outstanding
- 4.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 13, 2015
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $10.8M in FY2025.
- Trading 34% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review KIORA PHARMACEUTICALS INC.
Write a review
News about KIORA PHARMACEUTICALS INC
News & sentiment via Polygon.io
